DOCSLIB.ORG

Cigna Standard 4-Tier Prescription Drug List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cigna Standard 4-Tier Prescription Drug List CIGNA STANDARD 4-TIER PRESCRIPTION DRUG LIST For California Health Maintenance Organization, Point of Service, Network, Preferred Provider Organization, Exclusive Provider Organization, Open Access Plus, Open Access Plus IN Network, LocalPlus, LocalPlus IN Coverage as of July 1, 2021 View your drug list online: View your coverage info online: Cigna.com/druglist myCigna® App or myCigna.com 24/7 Customer Service: 800.Cigna24 (800.244.6224) Offered by: Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, or their affiliates. 927830 c CA Standard 4-Tier 06/21 Last updated: 06/01/2021. This drug list is subject to change and all prior versions are no longer in effect. What’s inside? Information about the drug list 3 Frequently asked questions (FAQs) 3 Words you may need to know 9 About this drug list 10 How to read this drug list 11 How to find your medication 14 List of prescription medications 16 Exclusions and limitations for coverage 145 Index of medications 146 View the drug list online This document was last updated 03/01/2021.* You can go online to see the current list of medications your plan covers. myCigna® App and/or myCigna.com. Click on the “Find Care & Costs” tab and select “Price a Medication.” Then type in your medication name to see how it’s covered. Cigna.com/PDL. Scroll down until you see the section for the Cigna Standard Prescription Drug List. Click on the pdf of the California 4 Tier – injectable specialty medications covered on Tier 4 (CDI). Questions? › Click to chat: myCigna website, Monday–Friday, 9:00 am–8:00 pm EST. › By phone: Call the toll-free number on your Cigna ID card. We’re here 24/7/365. * Drug list created: originally created 01/01/2004 Last updated: 06/01/2021, for changes Next planned update: 09/15/2021, for starting 07/01/2021 changes starting 01/01/2022 2 Information about the drug list Frequently asked questions (FAQs) Understanding your prescription medication coverage can be confusing. Here are answers to some commonly asked questions. Q. How often is the drug list updated? How do I know (P&T) Committee, which is a group of practicing if my medication coverage changed? doctors and pharmacists, most of whom work outside of Cigna. The group meets regularly to A. Cigna reviews and updates the prescription drug list every month. We make changes for many reasons – review medical evidence and information provided like when new medications become available or are by federal agencies, drug manufacturers, medical no longer available, or when medication prices professional associations, national organizations and change. We try to give you many options to choose peer-reviewed journals medications about the safety from to treat your health condition. These changes and effectiveness of medications that are newly may include:1,2 approved by the FDA and medications already on the market. The Cigna Pharmacy Management® › Moving a medication to a lower cost tier. This Business Decision Team then looks at the results of can happen at any time during the year. the P&T Committee’s clinical review, as well as the › Moving a brand medication to a higher cost tier medication’s overall value and other factors before when a generic becomes available. This can adding it to, or removing it from, the drug list. happen at any time during the year. Q. Why do certain medications need approval › Moving a medication to a higher cost tier and/or before my plan will cover them? no longer covering a medication. This typically A. The review process helps to make sure you’re happens twice a year on January 1st and July 1st. receiving coverage for the right medication, at › Adding extra coverage requirements to the right cost, in the right amount and for the a medication. right situation. When we make a change that affects the coverage Q. How do I know if I’m taking a medication that of a medication you’re taking, we let you know needs approval? before it happens. This way, you have time to talk A. Log in to the myCigna App or myCigna.com, or with your doctor about your options. check your plan materials, to learn more about Q. Why doesn’t my plan cover certain medications? how your plan covers your medications. If your medication has a (PA) or (ST) next to it, your A. To help lower your overall health care costs, your medication needs approval before your plan plan doesn’t cover certain high-cost brand will cover it. If it has a (QL) next to it, you may medications because they have lower-cost, covered need approval depending on the amount you’re alternatives which are used to treat the same filling. If it has (AGE) next to it, you may need condition. Meaning, the alternative works the same approval depending on the covered age range or similar to the non-covered medication. If you’re for the medication. taking a medication that your plan doesn’t cover and your doctor feels an alternative isn’t right Q. What types of medications typically need for you, he or she can ask Cigna to consider approval? approving coverage. A. Medications that: Your plan may also exclude certain medications or › May be unsafe when combined with other products from coverage. This is known as a “plan (or medications benefit) exclusion.” For example, your plan excludes medications that aren’t approved by the U.S. Food › Have lower-cost, equally effective alternatives and Drug Administration (FDA). With excluded available medications, there’s no option to receive coverage › Should only be used for certain health through Cigna’s coverage review process. conditions Q. How do you decide which medications to cover? › Are often misused or abused A. The Cigna Prescription Drug List is developed with the help of Cigna’s Pharmacy and Therapeutics 3 Q. What types of medications typically have doctor continues to prescribe it to treat your quantity limits? condition (as long as the medication is appropriately prescribed and is safe and effective in treating your A. Medications that: condition). › Are often taken in amounts larger than, or for longer than, may be appropriate Q. My plan doesn’t cover my medication. I need to take it because it’s medically necessary for my › Are often misused or abused treatment. How do I get approval (prior Q. What types of medications require Step Therapy? authorization) for my medication? A. The medications are used to treat many conditions, A. If your doctor feels that your medication is including, but not limited to: necessary for your treatment and an alternative isn’t right for you, he or she can ask Cigna to consider › ADD/ADHD › High cholesterol approving coverage of your medication. Ask your › Allergies › Osteoporosis doctor’s office to contact Cigna so we can start the › Bladder problems › Pain coverage review process. They know how the review process works and will take care of everything for Breathing problems Skin conditions › › you. In case the office asks, they can download a › Depression › Sleep disorders request form from Cigna’s provider portal at › High blood pressure cignaforhcp.com. Cigna will review information your doctor provides to make sure your medication Q. Why does my medication have an age meets coverage guidelines. If it does, you’ll be requirement? approved for coverage of the medication. If it A. Some medications are only considered clinically doesn’t meet guidelines, you and your doctor can appropriate if you’re within a certain age range. appeal the decision. We’ll send you information either way. Q. How do I get approval (prior authorization) for my medication? For non-urgent requests, Cigna will let you and your doctor know within 72 hours of the decision. If A. Ask your doctor’s office to contact Cigna so we can approved, coverage will be provided until the start the coverage review process. They know how prescription runs out (including refills). For urgent the review process works and will take care of requests based on exigent circumstances, Cigna will everything for you. In case the office asks, they can let you and your doctor know within 24 hours of the download a request form from Cigna’s provider decision. If approved, coverage will be provided for portal at cignaforhcp.com. Cigna will review the duration of the exigency. It’s important to know information your doctor provides to make sure your that when medications are approved, it’s typically medication meets coverage guidelines. If it does, for one year of coverage. If your medication is you’ll be approved for coverage of the medication. If approved for less time, it’s because there’s a clinical it doesn’t meet guidelines, you and your doctor can reason based on Cigna’s coverage guidelines for the appeal the decision. We’ll send you information medication and/or the reviewing doctor. either way. Q. My medication is part of the Step Therapy For non-urgent requests, Cigna will let you and your program. I don’t want to try an alternative. doctor know within 72 hours of the decision. If How do I get approval (prior authorization) for approved, coverage will be provided until the my medication? prescription runs out (including refills). For urgent requests based on exigent circumstances, Cigna will A. If you and your doctor feel an alternative medication let you and your doctor know within 24 hours of the won’t work for you, your doctor can ask Cigna to decision. If approved, coverage will be provided for consider approving coverage of your current the duration of the exigency.
Load more

Recommended publications
  • An Approach to the Patient with a Dry Mouth
    MedicineToday 2014; 15(4): 30-37 PEER REVIEWED FEATURE 2 CPD POINTS An approach to the patient with a dry mouth Key points • The subjective complaint of ELHAM AFLAKI MD; TAHEREH ERFANI MD; NICHOLAS MANOLIOS MB BS(Hons), PhD, MD, FRACP, FRCPA; xerostomia needs to be MARK SCHIFTER FFD, RCSI(Oral Med), FRACDS(Oral Med) differentiated from true salivary hypofunction. Dry mouth is a common and disabling problem. After exclusion of treatable • Salivary hypofunction can significantly reduce quality causes, treatment is symptomatic to prevent the consequences of salivary of life through its adverse hypofunction, such as tooth decay and infection of the oral mucosa. effects on taste, mastication, swallowing, cleansing of the erostomia, or the subjective feeling of neuropathic-induced orofacial dysaesthesia) mouth, killing of microbes a dry mouth, is a common complaint. and psychological and psychiatric disorders, and speech. It is often a consequence of salivary such as anxiety and depression. • Salivary hypofunction is a hypofunction (hyposalivation), in substantive risk factor for X which there is objective evidence of reduced NORMAL SALIVA PRODUCTION dental caries, oral mucosal salivary output or qualitative changes in saliva. Under normal physiological conditions, the disease and infection, Typically, patients complain of oral dryness salivary glands produce 1000 to 1500 mL of particularly oral candidiasis. only when salivary secretion is reduced by more saliva daily as an ultrafiltrate from the circu- • Patients should be than half.1 As saliva has a crucial role in taste lating plasma. Therefore, simple dehydration investigated for contributory perception, mastication, swallowing, cleansing reduces saliva production. The parotid glands and underlying causes, of the mouth, killing of microbes and speech, are the major source of serous saliva (60 to 65% which include drugs and abnormalities in saliva production can signif- of total saliva volume), producing the stimu- rheumatological diseases.
    [Show full text]
  • WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No
    WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 307 ,409 B2 Chase et al. (45 ) Date of Patent: Jun . 4 , 2019 ( 54 ) MUSCARINIC COMBINATIONS AND THEIR (52 ) U . S . CI. USE FOR COMBATING CPC . .. .. A61K 31/ 4439 (2013 . 01 ) ; A61K 9 /0056 HYPOCHOLINERGIC DISORDERS OF THE (2013 . 01 ) ; A61K 9 / 7023 ( 2013 . 01 ) ; A61K CENTRAL NERVOUS SYSTEM 31 / 166 ( 2013 . 01 ) ; A61K 31 / 216 ( 2013 . 01 ) ; A61K 31 /4178 ( 2013 .01 ) ; A61K 31/ 439 (71 ) Applicant: Chase Pharmaceuticals Corporation , ( 2013 .01 ) ; A61K 31 /44 (2013 . 01 ) ; A61K Washington , DC (US ) 31/ 454 (2013 .01 ) ; A61K 31/ 4725 ( 2013 .01 ) ; A61K 31 /517 (2013 .01 ) ; A61K 45 / 06 ( 72 ) Inventors : Thomas N . Chase , Washington , DC (2013 . 01 ) (US ) ; Kathleen E . Clarence -Smith , ( 58 ) Field of Classification Search Washington , DC (US ) CPC .. A61K 31/ 167 ; A61K 31/ 216 ; A61K 31/ 439 ; A61K 31 /454 ; A61K 31 /4439 ; A61K (73 ) Assignee : Chase Pharmaceuticals Corporation , 31 /4175 ; A61K 31 /4725 Washington , DC (US ) See application file for complete search history. ( * ) Notice : Subject to any disclaimer, the term of this (56 ) References Cited patent is extended or adjusted under 35 U . S . C . 154 (b ) by 0 days . U . S . PATENT DOCUMENTS 5 ,534 ,520 A 7 / 1996 Fisher et al. ( 21) Appl . No. : 15 /260 , 996 2008 /0306103 Al 12 /2008 Fisher et al. 2011/ 0021503 A1* 1/ 2011 Chase . .. A61K 31/ 27 ( 22 ) Filed : Sep . 9 , 2016 514 / 215 2011/ 0071135 A1 * 3 / 2011 Chase . .. .. .. A61K 31/ 166 (65 ) Prior Publication Data 514 / 215 2011 /0245294 Al 10 / 2011 Paborji et al.
    [Show full text]
  • Anthem Blue Cross Drug Formulary
    Erythromycin/Sulfisoxazole (generic) INTRODUCTION Penicillins ...................................................................... Anthem Blue Cross uses a formulary Amoxicillin (generic) (preferred list of drugs) to help your doctor Amoxicillin/Clavulanate (generic/Augmentin make prescribing decisions. This list of drugs chew/XR) is updated quarterly, by a committee Ampicillin (generic) consisting of doctors and pharmacists, so that Dicloxacillin (generic) the list includes drugs that are safe and Penicillin (generic) effective in the treatment of diseases. If you Quinolones ..................................................................... have any questions about the accessibility of Ciprofloxacin/XR (generic) your medication, please call the phone number Levofloxacin (Levaquin) listed on the back of your Anthem Blue Cross Sulfonamides ................................................................ member identification card. Erythromycin/Sulfisoxazole (generic) In most cases, if your physician has Sulfamethoxazole/Trimethoprim (generic) determined that it is medically necessary for Sulfisoxazole (generic) you to receive a brand name drug or a drug Tetracyclines .................................................................. that is not on our list, your physician may Doxycycline hyclate (generic) indicate “Dispense as Written” or “Do Not Minocycline (generic) Substitute” on your prescription to ensure Tetracycline (generic) access to the medication through our network ANTIFUNGAL AGENTS (ORAL) _________________ of community
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0108602 A1 Chu Et Al
    US 2003O1086O2A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0108602 A1 Chu et al. (43) Pub. Date: Jun. 12, 2003 (54) TABLETS AND METHODS FOR MODIFIED (22) Filed: Jul. 8, 2002 RELEASE OF HYDROPHILIC AND OTHER ACTIVE AGENTS Related U.S. Application Data (75) Inventors: James Shunnan Chu, Palo Alto, CA (63) Continuation of application No. 09/599,102, filed on (US); Yisong Yang, Sunnyvale, CA May 19, 2000, now Pat. No. 6,419,954. (US); Joseph A. Fix, Half Moon Bay, CA (US) Publication Classification Correspondence Address: (51) Int. Cl. ............................................... A61K 9/20 TOWNSEND AND TOWNSEND AND CREW, (52) U.S. Cl. .............................................................. 424/465 LLP TWO EMBARCADERO CENTER EIGHTH FLOOR (57) ABSTRACT SAN FRANCISCO, CA 94111-3834 (US) (73) Assignee: Yamanouchi Pharma Technologies, The invention provides a tablet and methods for making the Inc., Palo Alto, CA (US) tablet comprising a gel-forming material and at least one particle comprising an active agent in contact with a coating (21) Appl. No.: 10/191,979 material to modify release of the active agent. Patent Application Publication Jun. 12, 2003 Sheet 1 of 11 US 2003/0108602 A1 (O) N 3(O) 2(O) A/G /A Patent Application Publication Jun. 12, 2003. Sheet 2 of 11 US 2003/0108602 A1 O / O2 OOO OO O Q(SO39 O KC O () i88. OOO OO Okk (ki (k) <k. SJS19O OO <! o O OSS) O O 33 kg) O<< 3k 32 "ooO O & : A/6, 2O Patent Application Publication Jun. 12, 2003 Sheet 3 of 11 US 2003/0108602 A1 Active POWCer (Cevimeline HCI) Formulation Parameters -Pretreatment of Active -Binder: Solid or Solution Binder -% Content of Binder (HPC or PEO/PEG) -Amount of Water Process Parameters -Equipment Selection -Spray Technique Pelletization -Product Temperature (Granulation) -Drying Procedure Process -Milling Technique -High Shear G -Fluid-Bed G In-Process Tests -Yield Active Pellet/Granules -Physical Characteristics -ASSay FIG.
    [Show full text]
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • (Tert- Butoxycarbonyl)Amino](3 361442- 3
    Alternative Name CAS 1. Product Name Use Number 320345- 2. Aclidinium bromide API 99-1 (2S)-[(tert- Butoxycarbonyl)amino](3 361442- 3. Saxagliptin int -hydroxyadamant-1- 00-4 yl)ethanoic acid 1,3- 1,3- 5001-18- 4. Dihydroxyadamantane Adamantanediol 3 1,3-Dimethyladamantane 702-79-4 memantine intermediate 5. 1-Acetylamido-3,5- 19982- 6. Memantine int dimethyladamantane 07-1 1- 7. 880-52-4 Acetylaminoadamantane 1- 4942-47- 8. 1-Adamantaneacetic acid Adamantylacetic 6 acid [2-(1- 6240-11- 9. 1-Adamantaneethanol Adamantylethano 5 l)] 1- 10. 1-Adamantanemethanol Adamantylmetha 770-71-8 nol 1- 1660-04- 1-Adamantyl methyl rimantadine intermediate; 11. Acetyladamantan 4 ketone e 1-Chloro-3,5- 707-36-8 memantine intermediate; 12. dimethyladamantane 1-Hydroxy-3,5- memantine intermediate; 13. 707-37-9 dimethyladamantane 2- 14. 2-Adamantanol Hydroxyadamant 700-57-2 ane 15. 2-Adamantanone 700-58-3 2-Aminoadamantane 10523- 16. hydrochloride 68-9 3-Amino-1-hydroxy- 3-Amino-1- 702-82-9 vildagliptin intermediate; 17. adamantane adamantanol 3- 38584- 18. (Hydroxymethyl)adamant 37-1 -1-ol 19. 3-aminomethyl- 865887- mequitazine intermediate; 20. quinuclidine 14-5 dihydrochloride zacopride intermediate; 6530-09- mezacopride intermediate; 3-Aminoquinuclidine 21. 2 pancopride intermediate; dihydrochloride azasetron intermediate; 3-Carbethoxy-dehydro- quifenadine intermediate; 50790- 22. quinuclidine sequifenadine intermediate; 85-7 hydrochloride quifenadine intermediate; 3- 6238-33- 23. sequifenadine intermediate; Carbethoxyquinuclidine 1 3-hydroxymethyl 79221- mequitazine intermediate; 24. quinuclidine 75-3 hydrochloride 3-Quinuclidine 6238-34- 25. carboxylic acid 2 hydrochloride 1619-34- penehyclidine intermediate; 26. 3-Quinuclidinol 7 clidinium intermediate; cevimeline intermediate; 3-Quinuclidinone 1193-65- 27.
    [Show full text]
  • AL 2019 Rx90 Maintenance by Alpha Standard Member List Finalv3
    Prescription Drug Maintenance List Effective January 1, 2019 Below is the list of medications available for the Prescription Listing of oral contraceptives: Oral contraceptives are a Drug Maintenance List. This list is subject to change without part of this list and are included in the benefit. Please note, due notice. Please refer to your benefit to find out if the Prescription to the large number of brand names, this list may not reflect all Drug Maintenance List applies to your plan. available brands. Please note, generic drugs are available for many of the brand- name drugs listed. Some products noted as generics may not have generics for every strength. ADALAT CC – nifedipine tab er 24hr 30 mg ABILIFY – aripiprazole tab 2 mg ADALAT CC – nifedipine tab er 24hr 60 mg ABILIFY – aripiprazole tab 5 mg ADALAT CC – nifedipine tab er 24hr 90 mg ABILIFY – aripiprazole tab 10 mg ADLYXIN – lixisenatide soln pen-injector 20 mcg/0.2ml ABILIFY – aripiprazole tab 15 mg (100 mcg/ml) ABILIFY – aripiprazole tab 20 mg ADVAIR DISKUS – fluticasone-salmeterol aer powder ba ABILIFY – aripiprazole tab 30 mg 100-50 mcg/dose acarbose tab 25 mg (Precose) ADVAIR DISKUS – fluticasone-salmeterol aer powder ba acarbose tab 50 mg (Precose) 250-50 mcg/dose acarbose tab 100 mg (Precose) ADVAIR DISKUS – fluticasone-salmeterol aer powder ba ACCOLATE – zafirlukast tab 10 mg 500-50 mcg/dose ACCOLATE – zafirlukast tab 20 mg ADVAIR HFA – fluticasone-salmeterol inhal aerosol ACCUPRIL – quinapril hcl tab 5 mg 45-21 mcg/act ACCUPRIL – quinapril hcl tab 10 mg ADVAIR HFA – fluticasone-salmeterol
    [Show full text]
  • Acute Inhibitory Effects of Antidepressants on Lacrimal Gland Secretion in the Anesthetized Rat
    Physiology and Pharmacology Acute Inhibitory Effects of Antidepressants on Lacrimal Gland Secretion in the Anesthetized Rat Martin Dankis, Ozgu Aydogdu, Gunnar Tobin, and Michael Winder Department of Pharmacology, Institute of Neuroscience and Physiology, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden Correspondence: Michael Winder, PURPOSE. Patients that medicate with antidepressants commonly report dryness of eyes. Department of Pharmacology, The cause is often attributed to the anticholinergic properties of the drugs. However, regu- Institute of Neuroscience and lation of tear production includes a substantial reflex-evoked component and is regulated Physiology, the Sahlgrenska via distinct centers in the brain. Further, the anticholinergic component varies greatly Academy, University of Gothenburg, among antidepressants with different mechanisms of action. In the current study it was Medicinaregatan 13 413 90, Gothenburg, Sweden; wondered if acute administration of antidepressants can disturb production of tears by [email protected]. affecting the afferent and/or central pathway. Received: November 9, 2020 METHODS. Tear production was examined in vivo in anesthetized rats in the presence Accepted: May 10, 2021 or absence of the tricyclic antidepressant (TCA) clomipramine or the selective sero- Published: June 7, 2021 tonin reuptake inhibitor (SSRI) escitalopram. The reflex-evoked production of tears was Citation: Dankis M, Aydogdu O, measured by challenging the surface of the eye with menthol (0.1 mM) and choliner- Tobin G, Winder M. Acute inhibitory gic regulation was examined by intravenous injection with the nonselective muscarinic effects of antidepressants on agonist methacholine (1–5 μg/kg). lacrimal gland secretion in the RESULTS. Acute administration of clomipramine significantly attenuated both reflex- anesthetized rat.
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Your 2017 Three-Tier
    Your 2017 Three-Tier Prescription Drug List effective January 1, 2017 Connecticut Advantage Three-Tier Please read: This document contains information about commonly prescribed medications. This Prescription Drug List (PDL) is accurate as of January 1, 2017 and is subject to change after this date. The next anticipated update will be in July 2017. Your estimated coverage and copay/co-insurance may vary based on the benefit plan you choose and the effective date of the plan. For additional information: Call the toll-free member phone number on your health plan ID card. Visit myuhc.com® • Locate a participating retail pharmacy by ZIP code. • Look up possible lower-cost medication alternatives. • Compare medication pricing and options. 1 Your Prescription Drug List This Prescription Drug List (PDL) outlines covered medications for certain conditions and organizes them into cost levels, also known as tiers. An important part of the PDL is giving you choices so you and your doctor can choose the best course of treatment for you. Go to myuhc.com® for complete drug information Since the PDL may change, we encourage you to visit our website, myuhc.com. This website is the best source for up-to-date information about the medications your pharmacy benefit covers, possible lower-cost options, and cost comparisons. To view PDL information without logging on to the member portal, visit myuhc.com and select “Pharmacy Information” under “Links and Tools.” 2 At UnitedHealthcare, we want to help you better understand your medication options. Your pharmacy benefit offers flexibility and choice in determining the right medication for you.
    [Show full text]
  • 2021 Formulary (LIST of COVERED DRUGS)
    2021 Formulary CASE STUDY Car(LISTdinal AOFnalytx COVERED Solutions DRUGS) • Premera Blue Cross Medicare Advantage HMO Customer Service • Premera Blue Cross Medicare Advantage Classic (HMO) This formulary was updated on August 25, 2021. • Premera Blue Cross Medicare Advantage Classic Plus (HMO) For more recent information or • Premera Blue Cross Medicare Advantage Core (HMO) other questions, please contact Premera Blue Cross Medicare • Premera Blue Cross Medicare Advantage Core Plus (HMO) Advantage at 888-850-8526 (TTY/TDD: 711) October 1–March 31, • Premera Blue Cross Medicare Advantage Total Health (HMO) 8 a.m. to 8 p.m., 7 days a week April 1–Sept 30, 8 a.m. to 8 p.m., • Premera Blue Cross Medicare Advantage Charter + Rx (HMO) Monday through Friday, or visit premera.com/ma. • Premera Blue Cross Medicare Advantage Peak + Rx (HMO) Calls to this number are free. • Premera Blue Cross Medicare Advantage Sound + Rx (HMO) Customer Service also has free interpreter services available for • Premera Blue Cross Medicare Advantage Alpine (HMO) non-English speakers. WRITE: Premera Blue Cross Medicare Advantage Plans, PO Box 262548, Plano, TX 75026 PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN. 00021257, Version Number 14. Premera Blue Cross is an HMO plan with a Medicare contract. Enrollment in Premera Blue Cross depends on contract renewal. Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take. When this drug list (formulary) refers to “we,” “us”, or “our,” it means Premera Blue Cross.
    [Show full text]